See more : Bank of America Corporation (BAC-PP) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaTher Holdings Ltd. (PHRRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaTher Holdings Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Steamships Trading Company Limited (SST.AX) Income Statement Analysis – Financial Results
- Aisan Technology Co.,Ltd. (4667.T) Income Statement Analysis – Financial Results
- Lode Resources Ltd (LDR.AX) Income Statement Analysis – Financial Results
- enGene Holdings Inc. Common Stock (ENGN) Income Statement Analysis – Financial Results
- Ilex Medical Ltd (ILX.TA) Income Statement Analysis – Financial Results
PharmaTher Holdings Ltd. (PHRRF)
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.42K | 1.78K | 355.00 | 0.00 |
| Gross Profit | 0.00 | -1.42K | -1.78K | -355.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.14M | 3.02M | 2.61M | 751.54K | 0.00 |
| General & Administrative | 904.37K | 941.72K | 1.36M | 1.68M | 142.90K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 23.67K |
| SG&A | 904.37K | 941.72K | 1.36M | 1.68M | 23.82K |
| Other Expenses | 0.00 | 24.99K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.04M | 4.01M | 4.10M | 2.82M | 23.82K |
| Cost & Expenses | 3.04M | 4.01M | 4.10M | 2.82M | 23.82K |
| Interest Income | 0.00 | 206.82K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 711.00 | 1.42K | 1.78K | 355.00 | 142.90K |
| EBITDA | -3.04M | -3.96M | -3.96M | -2.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.04M | -1.38M | -3.97M | -8.52M | -23.82K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -71.26K | -2.46M | -274.03K | 5.32M | 0.00 |
| Income Before Tax | -3.12M | -6.42M | -4.24M | 2.89M | -23.82K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.43M | -225.05K | 225.05K | -142.90 |
| Net Income | -3.12M | -6.42M | -4.01M | 2.66M | -23.82K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.07 | -0.05 | 0.04 | 0.00 |
| EPS Diluted | -0.04 | -0.07 | -0.05 | 0.04 | 0.00 |
| Weighted Avg Shares Out | 88.23M | 88.17M | 81.11M | 64.56M | 34.08M |
| Weighted Avg Shares Out (Dil) | 88.23M | 88.17M | 81.11M | 73.26M | 34.08M |
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaTher Announces Update on FDA New Drug Application for Ketamine
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaTher's Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PharmaTher's Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
Source: https://incomestatements.info
Category: Stock Reports